FEATURED EDITORIAL
Isolators are powerful tools, but they do not automatically ensure compliance with EU GMP Annex 1. RABS are frequently dismissed too quickly. The difference is not the technology itself, but how it is applied.
- CDMO Capacity Crunch: Are Biotechs Wasting Time On The Wrong CDMO?
- April 2026 — CDMO Opportunities And Threats Report
- Tackling The Cell & Gene Therapy Sector's Practical Post-Approval Problem
- Why Your MES RFP Is Failing Before It Starts
- Here's How FDA's Accelerated Approval Pathway Has Evolved Since '24
- Gaining An Edge In GLP-1 Production
- Kodak Flips The Script To Biopharma Manufacturing In Rochester
GUEST COLUMNISTS
-
April 2026 — CDMO Opportunities And Threats Report
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
-
Tackling The Cell & Gene Therapy Sector's Practical Post-Approval Problem
As the regulatory landscape continues to evolve, cell and gene therapy companies must plan post-approval change programs with regulatory monitoring built in from the start.
-
Why Your MES RFP Is Failing Before It Starts
Many manufacturing execution system requests for proposals fail. Not because vendors cannot deliver or the tech is immature, but because the requirements are written backward.
-
Here's How FDA's Accelerated Approval Pathway Has Evolved Since '24
FDA's accelerated approval guidance kicked off a rebalancing of new drug approval pathways. Since its 2024 release, the agency has been building on it in a few key areas.
-
Gaining An Edge In GLP-1 Production
The shortage-driven production of GLP-1 drugs of the past few years is giving way to a long-term operation model characterized by digital enablement and supply chain resilience.
-
How Generic Pharma Manufacturers Can Rebuild Margins Inside The Four Walls
The pricing dynamics for generic drugs turns formerly attractive products into high-volume, low-margin commodities. Lean and Six Sigma in four key areas can unlock efficiencies.
-
Causal Mechanism And Effect Analysis (CMEA): FMEA's Simpler, Effective Alternative
This article describes causal mechanism and effect analysis (CMEA) as an alternative to failure mode and effect analysis (FMEA) for analyzing and managing the industry’s risks.
-
The Stepwise Path Lilly Mapped From Paper To Digital Logbooks
Eli Lilly and Company started at the front lines, on the shop floor gathering operator input, when switching from paper to digital logbooks.
PHARMA OUTSOURCING WHITE PAPERS
-
Aggregation In Antibody-Drug Conjugates: Causes And Mitigation
Discover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.
-
Pharmaceutical Spray Drying – Technology And Applications
Explore the transformative potential of pharmaceutical spray drying in improving drug formulation, bioavailability, and delivery through versatile and innovative applications.
-
Nose To Brain (N2B) Drug Delivery – Benefits And Challenges
Delve into the growing interest in drug delivery methods that target the brain and central nervous system via absorption into the bloodstream, specifically focusing on crossing the blood-brain barrier (BBB).
-
Unlock The Potential Of Pharmacovigilance Outsourcing
Outsourcing pharmacovigilance can reduce overhead, strengthen compliance, and free teams to focus on innovation. Examine what a well-structured global PV model actually looks like in practice.
-
Precision By Design: Drug Innovation Through Structure-Based Drug Design (SBDD)
Leverage structure-based drug design to gain deeper molecular insights, prioritize high-potential candidates, and accelerate your path from discovery to clinic.
-
Engineering Reliability In Cell Therapy Manufacturing
A cell therapy manufacturing model built on precision planning, digital execution, lifecycle‑ready CMC systems, and transparent collaboration to achieve high reliability and reduce variability across programs.
PHARMA OUTSOURCING APP NOTES & CASE STUDIES
NEWSLETTER ARCHIVE
- 05.12.26 -- West Vantage: End-to-End Combination Product Solutions
- 05.12.26 -- C> CDMOs: On The Path To $75 Billion In Services?
- 05.11.26 -- STREAM Edition: Power Your Pipeline — Stream GMP, CDMO & Clinical Supply Insights
- 05.11.26 -- At INTERPHEX 2026 A Smarter Outsourcing Playbook Comes Into Focus
REPORTING
PRODUCTS & SERVICES
ON-DEMAND WEBINARS
- From Insights To Impact: Predictive Models And PAT For More Efficient And Robust Biologics Manufacturing
- Spray Dried Biologics For Pulmonary Dosage Forms
- Early Developability Assessment For Antibody Based Therapeutics
- Enhancing Gene Editing Outcomes And Safety for Clinical Translation With Next Generation Vectors
- Spray Dried Biologics For Nasal Dosage Forms